Electrophysiological Improvements in Patients with Dravet Syndrome Following Treatment with Zorevunersen, an Investigational Antisense Oligonucleotide (S19.001)

June 9, 2026Neurology

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to assess EEG δ-power as a potential biomarker reflecting the efficacy of zorevunersen in patients with Dravet syndrome.
Evaluated EEG δ-power before and after zorevunersen treatment in patients with Dravet syndrome.
Used electroencephalogram as a tool to measure changes in neural activity.
Investigational setting focusing on treatment response to antisense oligonucleotide therapy.
Significant improvements in δ-power were observed post-treatment with zorevunersen, indicating positive response.
EEG changes correlated with clinical improvement in symptoms related to Dravet syndrome.

Evaluates EEG δ-power as a biomarker for zorevunersen response in Dravet syndrome, suggesting promising treatment outcomes.

To evaluate electroencephalogram (EEG) δ-power as a candidate biomarker of zorevunersen treatment response in patients with Dravet syndrome (DS).

No takes yet. Share an insight, caveat, or question.

Colenbier et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share